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Abstract
The human body is composed of diverse cell types with distinct functions. While it is known that
lineage specification depends on cell specific gene expression, which in turn is driven by
promoters, enhancers, insulators and other cis-regulatory DNA sequences for each gene1–3, the
relative roles of these regulatory elements in this process is not clear. We have previously
developed a chromatin immunoprecipitation-based microarray method (ChIP-chip) to locate
promoters, enhancers, and insulators in the human genome4–6. Here, we use the same approach to
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identify these elements in multiple cell types and investigated their roles in cell type-specific gene
expression. We observed that chromatin state at promoters and CTCF-binding at insulators are
largely invariant across diverse cell types. By contrast, enhancers are marked with highly cell
type-specific histone modification patterns, strongly correlate to cell type-specific gene expression
programs on a global scale, and are functionally active in a cell type-specific manner. Our results
defined over 55,000 potential transcriptional enhancers in the human genome, significantly
expanding the current catalog of human enhancers and highlighting the role of these elements in
cell type-specific gene expression.
We performed ChIP-chip analysis as previously described5 to determine binding of CTCF
(insulator-binding protein) and the coactivator p300, and patterns of histone modifications in
five human cell lines: cervical carcinoma HeLa, immortalized lymphoblast GM06690 (GM),
leukemia K562, embryonic stem cells (ES), and BMP4-induced ES cells (dES). We first
investigated 1% of the human genome selected by the ENCODE Consortium7, using DNA
microarrays consisting of 385,000 50-mer oligos that tile 30 million basepairs (bp) at 36bp
resolution. We examined mono- and tri-methylation of histone H3 lysine 4 (H3K4me1,
H3K4me3) and acetylation of histone H3 lysine 27 (H3K27ac) at well-annotated promoters,
reasoning that the state of these histone modifications would vary in a cell type-specific
manner. To our surprise, the chromatin signatures at promoters are remarkably similar
across all cell types (Figure 1A). Quantitative comparison of ChIP-chip enrichment (see
Supplementary Information) revealed highly-correlated histone modification patterns at
promoters across all cell types, with an average Pearson correlation coefficient of 0.71
(Figure S1A). This observation also holds for the larger set of Gencode promoters (Figure
S2).
Next, we identified putative insulators in the ENCODE regions for these cell types based on
CTCF binding, as mammalian insulators are generally understood to require CTCF to block
promoter-enhancer interactions3. We observed nearly identical CTCF binding sites (Table
S1, Figure S1E) and highly-correlated CTCF enrichment patterns across all five cell types
(Figure S1B), providing experimental support for the mostly cell type invariant function of
CTCF as suggested by DNase hypersensitivity mapping results8.
We then investigated transcriptional enhancers in the ENCODE regions, performing ChIP-
chip in HeLa, K562, and GM cells to locate binding sites for the transcriptional coactivator
protein p300 (Tables S2–S4) as p300 is known to localize at enhancers9. We observed
highly cell type-specific histone modification patterns at distal p300 binding sites (Figure
S1F), in sharp contrast to the similarities in histone modifications across cell types at
promoters. We then employed our chromatin signature-based prediction method5 to identify
additional enhancers in the ENCODE regions in these cell types (Figure 1B, Table S5–S9).
In addition to the characteristic H3K4me1 enrichment, predicted enhancers are frequently
marked by acetylation of H3K27, DNaseI hypersensitivity, and/or binding of transcription
factors and coactivators, and many contain evolutionarily conserved sequences (Figure S3–
S4, see Supplementary Information). Unlike promoters and insulators, but similar to p300
binding sites, the histone modification patterns at predicted enhancers are largely cell type-
specific (Figure 1B, S1D), in agreement with observations that H3K4me1 is distributed in a
cell type-specific manner10.
These results suggest that enhancers are the most variable class of transcriptional regulatory
element between cell types and are likely of primary importance in driving cell type-specific
patterns of gene expression. Knowledge of enhancers is therefore critical for understanding
mechanisms that control cell type-specific gene expression, yet our incomplete knowledge
of enhancers in the human genome has confined previous studies of gene regulatory
networks mainly to promoters. To identify enhancers on a genome-wide scale and facilitate
Heintzman et al. Page 2













global analysis of gene regulatory mechanisms, we performed ChIP-chip throughout the
entire human genome as described6, mapping enrichment patterns of H3K4me1 and
H3K4me3 in HeLa cells. Using previously described chromatin signatures for enhancers5,
we predicted 36589 enhancers in the HeLa genome (Figure 2A, Table S10, see
Supplementary Information). This method correctly located several previously characterized
enhancers, including the β-globin HS2 enhancer11 and distal enhancers for the PAX612 and
PLAT (t-PA)13 genes (Figure 2B). Most predicted enhancers are distal to promoters (Figure
2C), exhibit strong evolutionary conservation (see Supplementary Information), and are
marked by histone acetylation (H3K27ac), binding of coactivator proteins (p300, MED1), or
DNaseI hypersensitivity (DHS) (Figure 2A, 2D) (see Supplementary Information). We
verified the functional potential of predicted HeLa enhancers using luciferase reporter assays
as described5 (see Methods). Of nine predicted enhancers that we evaluated, seven (78%)
were active in reporter assays (Figure 2E, Table S11), with median activity significantly
different from random genomic regions (p = 3.25 × 10−4). These results support the
suitability of using chromatin signatures to identify genomic regions with enhancer function.
We evaluated the predicted enhancers for conserved motif-like sequences using several
hundred shuffled TRANSFAC motifs across 10 mammals in a phylogenetic framework that
tolerates motif movement, partial motif loss, and sequencing or alignment discrepancies (see
Methods). Predicted enhancers showed conservation for 4.3% of instances (at Branch-
Length-Score > 50%, see Methods), substantially greater than for the remaining intergenic
regions (2.9%, p < 1 × 10−100) and even promoter regions (3.9%, p = 1 × 10−57).
Additionally, testing a list of 123 unique TRANSFAC motifs as described14 (see
Supplementary Information), we found that 67 (54%) are over-conserved and 39 (32%) are
enriched in predicted enhancers (Table S12). We also performed de novo motif discovery in
enhancer regions using multiple alignments of 10 mammalian genomes (see Methods),
revealing 41 enhancer motifs, of which 19 match known transcription factor motifs while 22
are novel (Table S13). These motifs show conservation rates between 7% and 22% in
enhancers (median 9.3%), compared to only 1.1% for control shuffled motifs of identical
composition. Furthermore, over 90% of these motifs appear to be unique to enhancers, as
only 4 motifs are enriched in promoter regions and 12 are in fact depleted in promoters
(Table S13), indicating that predicted enhancers contain unique regulatory sequences that
may be specific to enhancer function.
To investigate the association of predicted enhancers with HeLa-specific gene expression,
we used Shannon entropy15 to rank genes by the specificity of their expression levels in
HeLa as compared to three other cell lines (K562, GM06990, IMR90) (Figure S5, see
Supplementary Information), then plotted the distribution of enhancers around genes within
insulator-delineated domains (as defined by CTCF binding sites in Figure S6, see
Supplementary Information). Predicted enhancers are strikingly enriched near HeLa-specific
expressed genes (Figure 3A), particularly within 200 kb of promoters. We observed a 1.83-
fold enrichment (p = 4.71 × 10−279) of predicted enhancers around HeLa-specific expressed
genes relative to random (see Supplementary Information) and significant depletion of
enhancers around non-specific expressed genes (p = 5.43 × 10−15) and HeLa-specific
repressed (p = 4.63 × 10−2) genes.
To more directly investigate the relationship between chromatin modification patterns at
enhancers and cell type-specific gene expression, we expanded our global analysis to
another cell type. We performed genome-wide ChIP-chip for H3K4me1 and H3K4me3 in
K562 cells and identified 24566 putative enhancers in this cell type using our chromatin
signature-based enhancer prediction method (Table S14) (see Supplementary Information).
Consistent with results in the ENCODE regions, the vast majority of enhancers predicted in
K562 and HeLa cells are unique to either cell type (Figure 3B) even though most expressed
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genes are common between the cell types (Figure 3C). Chromatin modification profiles at
predicted enhancers throughout the genome are highly cell type-specific (Figure 3D), with a
Pearson correlation coefficient of −0.32. Furthermore, these differences seem to have
regulatory implications, as domains with HeLa-specific expressed genes are enriched in
HeLa enhancers but depleted in K562 enhancers, and vice-versa (Figure 3E) (see
Supplementary Information). These observations hold across all five cell types in the
ENCODE regions (see Supplementary Information). To assess the cell type-specificity of
enhancer activity, we cloned enhancers predicted specifically in K562 cells (and not in HeLa
cells) and subjected them to reporter assays in HeLa cells as described above. Of nine K562-
specific enhancers tested, only two (22%) were active in HeLa cells (Figure S7), and the
median activity of the K-562 specific enhancers was not significantly different from random
(p = 0.11), suggesting that the enhancer chromatin signature is a reliable marker of cell type-
specific enhancer function.
Though most enhancers are cell type-specific, the presence of predicted enhancers shared by
HeLa and K562 (Figure 3B, 3D) suggests that some enhancers may be active in multiple cell
types or conditions. We compared the HeLa enhancer predictions with the results of several
genome-wide studies of binding sites for sequence-specific transcription factors in different
cell types, namely estrogen receptor16 (ER), p5317, and p6318 in MCF7, HCT116, and
ME180 cells, respectively. Interestingly, significant percentages of binding sites for each
transcription factor (from 21.4% to 32.6%) overlap with predicted enhancers in HeLa cells
(Figure 4A, Table S15), in sharp contrast to a significant depletion of the repressor NRSF/
REST19 at predicted enhancers and minimal overlap with CTCF-binding sites (see
Supplementary Information).
To examine the potential role of enhancers in regulating inducible gene expression, we
treated HeLa cells with the cytokine interferon-gamma (IFNγ) and identified binding sites
for the transcription factor STAT1 throughout the genome using ChIP-chip. STAT1
generally binds its target DNA sequences only after IFNγ induction20 with a small fraction
of binding possible prior to induction21. In IFNγ-treated HeLa cells, we identified 1969
STAT1 binding sites (Table S16), with 85.8% of STAT1 binding sites occurring distal to
Known Gene 5′-ends. Comparison of these distal STAT1 binding sites with recent ChIP-seq
analysis of STAT1 binding in uninduced HeLa cells21 shows only 6.5% of IFNγ-induced
STAT1 binding sites are occupied by STAT1 prior to induction. We observed that 429 distal
STAT1 binding sites overlapped enhancers predicted in HeLa cells prior to induction
(Figure 4A, Table S15). The H3K4me1 enhancer chromatin signature is present prior to
induction at these STAT1 binding sites, which we designated as STAT1 group I, while no
evidence of this signature is visible at the remaining 1260 distal STAT1 binding sites,
designated STAT1 group II (Figure 4B). Intriguingly, we observed significant relative
induction of expression of genes in the domains of STAT1 group I binding sites after just 30
minutes of IFNγ-induction, while induction levels remained relatively unchanged for genes
in the domains of other distal STAT1 group II binding sites during this time (Figure 4C).
These findings suggest that an enhancer chromatin signature confers increased regulatory
responsiveness to a STAT1 binding site, in agreement with our previous discovery of
functional enhancers in HeLa cells that were marked by the enhancer chromatin signature
but were not active until they were bound by STAT15.
Our findings offer the first genome-wide evaluation of the relationship between chromatin
modifications at transcriptional enhancers and global programs of cell type-specific gene
expression. We determined over 55,000 potential enhancers in the human genome and
showed that the chromatin modifications at the enhancers correlate with cell type-specific
gene expression and functional enhancer activity. Perhaps the most intriguing observation is
the large number of enhancers identified from the investigation of just two cell lines. Since
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enhancers are mostly cell type-specific, our data suggest the existence of a vast number of
enhancers in the human genome, on the order of 105–106, that are used to drive specific
gene expression programs in the 200 cell types of the human body. Future experiments with
diverse cell types and experimental conditions will be necessary to comprehensively identify
these regulatory elements and understand their roles in the specific gene expression program
of each cell type.
Methods Summary
HeLa, K562, and IMR90 cells were obtained from ATCC. GM06990 cells were acquired
from Coriell. All were cultured under recommended conditions. Passage 32 H1 cells were
cultured as described22 with/without 200ng/ml BMP4 for 6 days (RND systems). Chromatin
preparation, ChIP, DNA purification, and LM-PCR were performed as described using
commercially available and custom antibodies, and ChIP samples were hybridized to tiling
microarrays and to custom condensed enhancer microarrays (NimbleGen Systems, Inc.) as
described5,6. DNase-chip was performed and the data analyzed as described23. Cloning and
reporter assays were performed as described5. Data were normalized as described5 and
ChIP-chip targets for CTCF, p300, MED1, and STAT1 were selected with the Mpeak
program. We used MA2C24 to normalize and call peaks on Nimblegen HD2 arrays.
Enhancers were predicted and K-means clustering, intersection analysis, and evolutionary
conservation analysis were performed as described5. Motif analysis was performed as
described25. Gene expression was analyzed using HGU133 Plus 2.0 microarrays
(Affymetrix) as described5. Specificity of expression was determined using a function of
Shannon entropy15. We use the MAS5 algorithm from the Bioconductor R package to
generate gene expression Present/Absent calls. Detailed methods may be found in the
Supplementary Information. Supplementary data for the microarray experiments has been
formatted for viewing in the UCSC genome browser via
http://bioinformatics-renlab.ucsd.edu/enhancer
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chromatin modifications at promoters are cell type-invariant while those at enhancers
are cell type-specific
We employed ChIP-chip to map histone modifications (H3K4me1, H3K4me3, and
H3K27ac) in the ENCODE regions in five cell types (HeLa, GM, K562, ES, dES). (A) We
performed k-means clustering on the chromatin modifications found +/− 5 kb from 414
promoters, and observe them to be generally invariant across cell types. (B) As in (A), but
clustering on 1423 non-redundant enhancers predicted on the basis of chromatin signatures.
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Figure 2. Genome-wide enhancer predictions in human cells
(A) We predict 36589 enhancers in HeLa cells based on chromatin signatures for H3K4me1
and H3K4me3 as determined by ChIP-chip using genome-wide tiling microarrays and
condensed enhancer microarrays (see Supplementary Information). Enhancer predictions are
located at the center of 10 kb windows as indicated by black triangles, and ordered by
genomic position. Enrichment data are shown for histone modifications (H3K4me1,
H3K4me3, and H3K27ac), DNaseI hypersensitivity (DHS), and binding of p300 and MED1.
(B) ChIP-chip enrichment profiles at several known enhancers (indicated in red) recovered
by prediction: β-globin HS2 (chr11:5258371-5258665)11, PAX6
(chr11:31630500-31635000)12, PLAT (chr8:42191500-42192400)13 (5 kb windows
centered on enhancer predictions; images generated in part at the UCSC Genome Browser).
(C) Most enhancers have intergenic (56.3%) or intronic (37.9%) localization relative to
UCSC Known Gene 5′-ends. (D) Most enhancers (64.8%) are significantly marked by
DNaseI hypersensitivity, binding of p300, binding of MED1, or some combination thereof.
(E) 7 of 9 enhancers predicted in HeLa cells were active in reporter assays (red bars) as
compared to none of the random fragments selected as controls (gray), where activity is
defined as relative luciferase value greater than 2.33 standard deviations (p = 0.01) above
the median random activity (gray dashed line). Error bars represent standard deviation.
Regions of ~1–2kb in size were randomly selected for validation in reporter assays based on
histone modification patterns as in (A), overlap with features in (D), and sequence features
amenable to cloning via PCR (see Supplementary Information).
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Figure 3. Chromatin modifications at enhancers are globally related to cell type-specific gene
expression
(A) Enhancer localization relative to genes that are HeLa-specific expressed compared to
K562, GM06990, and IMR90 cells (red), non-specific expressed (green), HeLa-specific
repressed (black), and a random distribution (dashed grey). Predicted enhancers are enriched
around HeLa-specific expressed genes within insulator-defined domains and depleted in
domains of ubiquitous or non-expressed genes (p-value reflects significance of enhancer
enrichment in domains of HeLa-specific expressed genes, see Supplementary Information).
(B) Most enhancers predicted in HeLa and K562 cells are cell-type specific while (C) most
genes in HeLa and K562 cells are not specifically expressed; n = integer number of
enhancers or genes in each set. (D) Chromatin modification patterns are cell type-specific at
the majority of 55454 enhancers predicted in HeLa and K562 cells. (E) Comparison of
enhancer enrichment and differential gene expression between HeLa cells and K562 cells
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revealed that HeLa enhancers are enriched near HeLa-specific expressed genes (blue line)
while K562 enhancers are enriched near K562-specific expressed genes (orange line).
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Figure 4. Chromatin modifications are associated with increased regulatory response of
transcription factor binding sites at enhancers
(A) Predicted enhancers in steady-state HeLa cells overlap with significant fractions of
transcription factor binding sites (ER, p53, p63) in diverse cell types (MCF7, HCT116,
ME180), as well as with STAT1 binding sites in HeLa cells treated with the cytokine
interferon-gamma (HeLa-IFNγ) (TFBS = Transcription factor binding sites, TF =
Transcription Factor). (B) Hundreds of STAT1 binding sites after treatment (+IFNγ) are
marked by the enhancer chromatin signature in HeLa cells even prior to treatment (−IFNγ).
(C) In HeLa cells treated with IFNγ (upper panel), gene expression is significantly (p = 5.8 ×
10−8) more likely to be induced by STAT1 binding at sites with the enhancer chromatin
signature (red, STAT1 group I) than by STAT1 binding at other distal sites (red, STAT1
group II) relative to a random distribution (gray). Error bars represent standard deviation.
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